Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01271
|
|||||
| Drug Name |
Levomepromazine
|
|||||
| Synonyms |
2-Methoxytrimeprazine; 60-99-1; 9G0LAW7ATQ; Arc-VI-C-5; Bayer 1213; CL 36467; CL 39743; Dedoran; EINECS 200-495-5; F-5116; Hirnamine; Levomepromazin; Levomepromazina; Levomepromazina [INN-Spanish]; Levomepromazinum; Levomepromazinum [INN-Latin]; Levopromazioni; Levoprome; Levotomin; METHOTRIMEPRAZINE; Methotrimeprazine; Methotrimeprazine (USP); Methotrimeprazine [USP]; Methoxytrimeprazine; Milezin; Minozinan; Neozine; Nirnamine; Nocinan; Nomizan; Nosinan; Nozinan; RP-7044; UNII-9G0LAW7ATQ; Veractil; XP03
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Bipolar disorder [ICD11: 6A60-6A61] | Approved | [1] | |||
| Psychosis [ICD11: 6A2Y] | Approved | [1] | ||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H24N2OS
|
|||||
| Canonical SMILES |
CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C
|
|||||
| InChI |
InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1
|
|||||
| InChIKey |
VRQVVMDWGGWHTJ-CQSZACIVSA-N
|
|||||
| CAS Number |
CAS 145068
|
|||||
| Pharmaceutical Properties | Molecular Weight | 328.5 | Topological Polar Surface Area | 41 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
4.7
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:10124
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Levomepromazine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.